MRK - Merck & Co., Inc.
| Previous Close | 60.090 |
| Open | 59.900 |
| Bid | 59.07 x 300 |
| Ask | 59.08 x 900 |
| Day's Range | 59.010 - 59.920 |
| 52 Week Range | 52.830 - 66.410 |
| Volume | 3,274,724 |
| Avg. Volume | 12,770,116 |
| Market Cap | 159.072B |
| Beta | 1.11 |
| PE Ratio (TTM) | 67.90 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.92 (3.38%) |
| Ex-Dividend Date | 2018-03-14 |
| 1y Target Est | N/A |
- Market Realist•4 minutes ago
Novartis Launches FocalView to Modernize Clinical Trials
Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.
- Market Realist•4 minutes ago
Analysts’ Estimates for Sanofi’s 1Q18 Earnings
Paris-headquartered Sanofi (SNY), one of the world’s largest pharmaceutical companies, reports its financial results in euros. The company is set to release its 1Q18 earnings on April 27. Analysts expect Sanofi to report EPS (earnings per share) of 1.13 euros and revenue of 8.1 billion euros.
Market Realist•2 hours agoNovo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.
- Market Realist•2 hours ago
How Did Johnson & Johnson’s Consumer Segment Perform in 1Q18?
Johnson & Johnson’s (JNJ) consumer business includes various beauty products, baby care products, oral care products, over-the-counter products, women’s health products, and wound care products. The company’s consumer business reported 5.3% growth in revenues to $3.4 billion during 1Q18 as compared to $3.2 billion during 1Q17. The above chart compares the revenues of the various franchises in the consumer segment business since 1Q17.
- Market Realist•3 hours ago
What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?
Headquartered in New York City, Bristol-Myers Squibb (BMY) is one of the leading American pharmaceutical companies. Bristol-Myers Squibb’s portfolio includes various cardiovascular products, neuroscience products, immunoscience products, oncology products, and virology products.
- Market Realist•3 hours ago
Why Incyte Stock Fell ~9% on April 24
On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.
- Zacks•3 hours ago
What's in the Cards for Merck (MRK) This Earnings Season?
Merck's (MRK) new products like Keytruda and Bridion are likely to drive first-quarter sales. However, headwinds remain in the form genericization of key drugs and increasing competition.
- Market Realist•19 hours ago
Gilead Sciences Focuses on Its Liver Disease Portfolio
By mid-2018, Gilead Sciences (GILD) expects its share of the HCV (hepatitis C) market, where it competes with AbbVie (ABBV), Merck (MRK), and Bristol-Myers Squibb (BMY), to stabilize. This stabilization is anticipated despite rapidly declining drug prices and reducing treatment duration due to new and better therapies. While the company is not expecting any disruptive product launches in the HCV segment in the next few years, it expects gradually declining patient numbers to affect revenue. Liver disease research programs
- Market Realist•yesterday
How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.
- Motley Fool•yesterday
Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma
It's a lot easier to be patient once those quarterly payments start adding up.
Market Realist•yesterdayHenry Schein to Merge Animal Health with Vets First Choice
On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp., aimed to advance animal healthcare and benefit veterinarians, pets, product manufacturers, and pet owners. Henry Schein, one of the world’s largest global supply chain providers of animal health products, has established a top market position in North America, Europe, Australia, and New Zealand.
- InvestorPlace•yesterday
The Treasury Yield Is Trembling on the Edge of 3%
U.S. equities finished near the unchanged line on Monday as investors braced for the beginning of a very busy week of earnings reports. And much attention is being paid in the rise in long-term interest rates, with the 10-year Treasury yield within millimeters of crossing the 3% threshold (2.998%).
- Investopedia•yesterday
Merck Shares Seen Rising 12% as Profits Jump
Merck & Co. Inc.'s ( MRK) stock has had a rough three years with shares rising by a little more than 4%, versus an S&P 500 that has climbed by nearly 27%. The average price target on the stock is $67.68, nearly 12% higher than the stock's current price around $60.30. The chart shows a solid uptrend that has been in place for Merck since 2009—a decade-long uptrend.
- Reuters•yesterday
AstraZeneca flop a fresh blow to cancer immunotherapy combination
The concept of combining two immunotherapy drugs to fight lung cancer - not so long ago one of the hottest ideas in cancer research - has suffered a fresh blow from the failure of an AstraZeneca clinical study. Adding the company's experimental drug tremelimumab to its existing product Imfinzi failed to slow disease progression or extend life in patients who had already received at least two previous treatments, the drugmaker said on Tuesday.
- Investopedia•yesterday
AstraZeneca’s Lung Cancer Duo Flops
AstraZeneca’s combo of the experimental drug tremelimumab and Imfinzi failed to slow disease progression or extend life for lung cancer patients
- MarketWatch•2 days ago
Merck's stock surges to lead Dow's gainers after Goldman turns bullish
Shares of Merck & Co. Inc. ran up $1.61, or 2.7%, to a near three-month high in afternoon trade Monday, enough to pace the Dow Jones Industrial Average's gainers, after Goldman Sachs turned bullish on ...
- Benzinga•2 days ago
Keytruda Is Key To The Merck Thesis, Goldman Sachs Says In Upgrade
The Merck & Co., Inc. (NYSE: MRK ) story has slowly captivated analysts, and on Monday the pharmaceutical company corralled Goldman Sachs in its growing bullpen. The Rating Analyst Jami Rubin upgraded ...
- Reuters•2 days ago
P&G to buy German Merck's consumer health unit for $4.2 billion
The maker of Pampers diapers and Gillette razors said the deal would help it expand its portfolio of consumer healthcare products which includes Vicks cold relief. The Merck unit includes vitamin brands Femibion and Neurobion. The deal follows GlaxoSmithKline agreeing to buy Novartis out of their consumer healthcare joint venture for $13 billion after dropping its pursuit of Pfizer's consumer unit.
- Market Realist•2 days ago
Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
- Market Realist•2 days ago
Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.
- Market Realist•2 days ago
What Analysts Predict for GlaxoSmithKline’s 1Q18 Earnings
GlaxoSmithKline (GSK) is set to release its 1Q18 earnings on April 25, 2018. The below chart shows the company’s revenues and earnings per share (or EPS) since 1Q17 and analysts’ estimates for 1Q18. Analysts estimate the company will post EPS of 24.21 pence on revenues of 7.2 billion pounds in 1Q18.
Investing.com•3 hours agoMerck Gets Another Upgrade Thanks To Keytruda
Investing.com - Goldman Sachs (NYSE:GS) is the latest Wall Street firm to upgrade Merck (NYSE:MRK) because of the blockbuster potential of its cancer drug Keytruda.The firm upgraded Merck from neutral to buy, while adding it to its list of favorite stocks. In a note to clients, Morgan Stanley (NYSE:MS) said Keytruda sales, which doubled to $3.8 billion in 2017, could soar to $16 billion by 2025.Keytruda is widely expected to gain a larger share of the market for non-small cell lung cancers. It's currently approved for lung, skin and stomach cancers, and is being tested for still others. Morgan Stanley, Barclays (LON:BARC) and Leerick Partnters have all recently upgraded the stock and/or raised their price targets. Merck shares, however, are down 5% over the past 12 months.
Yahoo Finance Video•2 days agoAkorn, Henry Schein and Merck are the Yahoo Finance charts of the day.
Akorn (AKRX): Shares tumbling here, down over 33%. It’s bad news for the generic drugmaker, as Germany’s Fresenius is ditching its plan to buy Akorn following allegations of breaches of FDA data integrity rules. Henry Schein (HSIC): Shares climbing in early trade, up around 6%. The health care products maker is going to spin off and merge its Animal Health business with startup Vets First Choice, an online platform for veterinarians. Merck (MRK): Shares up here in early trade, down around 2%. Rounding out our third health care related stock here, Merck shares are rallying following a rare double-upgrade by Goldman to Conviction Buy, citing its Keytruda lung cancer breakthrough. For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.
